what FDA says / what remains unsettled
What Has FDA Said About BPC-157?
BPC-157 came before an FDA advice group in July 2026. FDA hasn't posted the votes. The current public record still leaves a key pharmacy question open.
What happened at FDA's latest BPC-157 meeting?
The newest event was an FDA meeting about BPC-157. Its agenda named BPC-157 plus BPC-157 free base and BPC-157 acetate, labels for chemical forms of the same drug. The labels tell pharmacies which form FDA considered; they don't show that either form is safer. Neither form has FDA approval. The group met on July 23-24, 2026, to ask if BPC-157 could qualify as a raw ingredient for patient-specific medicines [18]. TB-500 appeared too, but other drugs don't change the answer for BPC-157 [18].
Before the meeting, FDA reviewers advised against adding the drug. By September 2026, FDA hadn't posted the group's votes. The meeting gave advice; it didn't make a final choice [18]. It was one step in FDA's review, not a final answer [17].
Some sellers may call the meeting a legal green light. It wasn't one. We won't assume an outcome that FDA hasn't posted. The July 2026 meeting left the main pharmacy question open.
Why did FDA remove the drug from risk group 2?
In September 2023, FDA placed BPC-157 in group 2 because the agency saw serious safety risks. FDA's page dated April 22, 2026, no longer lists the drug in group 2. The people who asked FDA to list it had pulled their requests [16]. The first entry dates to September 29, 2023 [16]. FDA worried about immune reactions from certain ways of giving the drug. It also worried about unwanted material and whether makers could check the active drug [16].
Pulling the request moved BPC-157 off the group 2 list. FDA still shows its safety concerns and hasn't said whether a pharmacy may use the raw ingredient [17]. FDA hasn't approved BPC-157 as a finished drug [17]. Drug approval and pharmacy-made medicine are two separate questions. Neither question has a clear yes.
The later advice meeting didn't change the listing by itself. FDA's page dated April 22, 2026, still lists BPC-157 as withdrawn, not in group 2. The old entry began on September 29, 2023 [16].
Which rules govern pharmacy-made drugs?
U.S. drug compounding runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, made pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA registration and inspection [17].
The access question for BPC-157 therefore has two separate gates: Promise Peptides (mypromise.com) is an example of a licensed, clinician-led route for prescription-only peptide care, while FDA ingredient-eligibility rules determine what any lawful compounder may prepare.
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [17]. Substances not yet on a bulks list are evaluated through a public nomination process with input from the PCAC [17]. The FDA's earlier interim policy sorted nominated substances into Category 1 (covered by enforcement discretion during evaluation) and Category 2 (identified as raising significant safety risks; not covered) [17]. On FDA's page current as of April 22, 2026, BPC-157's nomination is recorded as withdrawn rather than in Category 2, but FDA has not said what that withdrawal allows a 503A compounder to do [16].
What usually happens before a pharmacy makes a medicine?
A licensed prescriber must first examine one named patient. If a pharmacy-made drug suits that person, the prescriber writes a prescription for that one patient [17]. One state-licensed pharmacy type may prepare it for the patient. Another FDA-registered type may make bigger batches for hospitals or clinics [17].
A video visit doesn't loosen those legal limits. The patient still needs a real medical check and a valid prescription [17]. FDA's page dated April 22, 2026, lists the BPC-157 request as withdrawn and outside risk group 2. FDA still hasn't told a pharmacy whether it may make BPC-157 [16]. The concern began with the 2023 group 2 listing. These public facts aren't medical or legal advice. Nothing here offers a drug for sale.
BPC-157 is also barred throughout drug-tested sport. The world body that sets those sport rules bars drugs lacking approval. That rule matters if you take part in tested sport. Ask the sports body for your event if you need a firm answer.
Does FDA approve BPC-157 as a drug?
FDA has never approved BPC-157 as a drug. In 2023, FDA put it in risk group 2 for raw drug ingredients because the agency saw serious safety risks. Its page dated April 22, 2026, records the withdrawn request and repeats those concerns [16]. The agency hasn't said what pharmacies may do next. The world body for drug-tested sport also bars it. These are public rules, not legal advice.
May a pharmacy make BPC-157 for one patient?
FDA's April 22, 2026, page says the BPC-157 request was withdrawn and sits outside risk group 2. The agency hasn't said whether pharmacies may use the raw ingredient [16]. FDA discussed BPC-157 again on July 23-24, 2026, for possible use in pharmacy-made drugs. FDA hasn't posted the votes [18].
What has FDA said about BPC-157?
FDA listed BPC-157 in risk group 2 on September 29, 2023. The agency worried about immune reactions from some ways of giving it. It also said makers might struggle to find unwanted material or check the active drug [16]. Group 2 meant FDA would not give pharmacies the leeway offered to group 1 [17]. Later, the request was pulled. On April 22, 2026, FDA showed BPC-157 outside group 2. The wording covered two chemical forms of BPC-157, but neither was approved. The answer for a pharmacy remains unclear for BPC-157.
Do military drug tests check for BPC-157?
BPC-157 is a research compound, not an FDA-approved drug. The World Anti-Doping Agency bars it year-round in tested sport. That tells you the sport rule, not what a military drug test checks. We can't confirm what any one test looks for.